All In Biotech

NDA 050640 · Baxter Hlthcare

Bactocill In Plastic Container

Oxacillin Sodium · Injection

Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Oct 26, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

55

12 Phase 3, 5 recruiting

FAERS reports

980

917 serious, 189 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

INDICATIONS AND USAGE Oxacillin is indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug. (See CLINICAL PHARMACOLOGY - Susceptibility Test Methods .) Oxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. Oxacillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant Staphylococcus , therapy should not be continued with oxacillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Oxacillin Injection, USP and other antibacterial drugs, Oxacillin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Mechanism of Action Penicillinase-resistant penicillins exert a bactericidal action against penicillin susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 26, 1989 Original approval · Type 3 - New Dosage Form
2 products under this application
  • BACTOCILL IN PLASTIC CONTAINER · OXACILLIN SODIUM EQ 40MG BASE/ML · INJECTABLE, INJECTION · Prescription
  • BACTOCILL IN PLASTIC CONTAINER · OXACILLIN SODIUM EQ 20MG BASE/ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxacillin" as an intervention, any sponsor and status, largest first.

All 55 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective90
  • acute kidney injury63
  • drug reaction with eosinophilia and systemic symptoms54
  • pyrexia49
  • rash48
  • drug interaction42
  • off label use39
  • staphylococcal infection35
  • toxic epidermal necrolysis35
  • pneumonia34
  • renal failure33
  • alanine aminotransferase increased31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200444
200527
200625
200730
200818
200930
201015
201137
201253
201316
201455
201553
201649
201757
201874
201948
202074
202159
202248
202346
202436
202547
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 117 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.